Copyright Reports & Markets. All rights reserved.

Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size, Status and Forecast 2020-2026

Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size Growth Rate by Type: 2020 VS 2026
    • 1.2.2 Pertuzumab
    • 1.2.3 Trastuzumab
  • 1.3 Market by Application
    • 1.3.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share by Application: 2020 VS 2026
    • 1.3.2 Combination Therapy
    • 1.3.3 Mono Therapy
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Perspective (2015-2026)
  • 2.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Growth Trends by Regions
    • 2.2.1 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Historic Market Share by Regions (2015-2020)
    • 2.2.3 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Players by Market Size
    • 3.1.1 Global Top Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Players by Revenue (2015-2020)
    • 3.1.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue Market Share by Players (2015-2020)
  • 3.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue
  • 3.4 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Concentration Ratio
    • 3.4.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Revenue in 2019
  • 3.5 Key Players Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Area Served
  • 3.6 Key Players Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Product Solution and Service
  • 3.7 Date of Enter into Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Breakdown Data by Type (2015-2026)

  • 4.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Historic Market Size by Type (2015-2020)
  • 4.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecasted Market Size by Type (2021-2026)

5 Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Breakdown Data by Application (2015-2026)

  • 5.1 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Historic Market Size by Application (2015-2020)
  • 5.2 Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size (2015-2026)
  • 6.2 North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2015-2020)
  • 6.3 North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2015-2020)
  • 6.4 North America Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size (2015-2026)
  • 7.2 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2015-2020)
  • 7.3 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2015-2020)
  • 7.4 Europe Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic
    • 7.4.7 Rest of Europe

8 China

  • 8.1 China Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size (2015-2026)
  • 8.2 China Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2015-2020)
  • 8.3 China Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2015-2020)
  • 8.4 China Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia
    • 8.4.7 Rest of Asia-Pacific

9 Japan

  • 9.1 Japan Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size (2015-2026)
  • 9.2 Japan Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2015-2020)
  • 9.3 Japan Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2015-2020)
  • 9.4 Japan Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Southeast Asia

  • 10.1 Southeast Asia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size (2015-2026)
  • 10.2 Southeast Asia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Type (2015-2020)
  • 10.3 Southeast Asia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Application (2015-2020)
  • 10.4 Southeast Asia Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE
    • 10.4.4 Rest of Middle East & Africa

11Key Players Profiles

  • 11.1 Roche
    • 11.1.1 Roche Company Details
    • 11.1.2 Roche Business Overview
    • 11.1.3 Roche Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Introduction
    • 11.1.4 Roche Revenue in Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Business (2015-2020))
    • 11.1.5 Roche Recent Development
  • 11.2 BOC Sciences
    • 11.2.1 BOC Sciences Company Details
    • 11.2.2 BOC Sciences Business Overview
    • 11.2.3 BOC Sciences Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Introduction
    • 11.2.4 BOC Sciences Revenue in Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Business (2015-2020)
    • 11.2.5 BOC Sciences Recent Development
  • 11.3 LGM Pharma
    • 11.3.1 LGM Pharma Company Details
    • 11.3.2 LGM Pharma Business Overview
    • 11.3.3 LGM Pharma Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Introduction
    • 11.3.4 LGM Pharma Revenue in Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Business (2015-2020)
    • 11.3.5 LGM Pharma Recent Development
  • 11.4 Biotechnica Pharma Global
    • 11.4.1 Biotechnica Pharma Global Company Details
    • 11.4.2 Biotechnica Pharma Global Business Overview
    • 11.4.3 Biotechnica Pharma Global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Introduction
    • 11.4.4 Biotechnica Pharma Global Revenue in Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Business (2015-2020)
    • 11.4.5 Biotechnica Pharma Global Recent Development
  • 11.5 KinBio
    • 11.5.1 KinBio Company Details
    • 11.5.2 KinBio Business Overview
    • 11.5.3 KinBio Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Introduction
    • 11.5.4 KinBio Revenue in Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Business (2015-2020)
    • 11.5.5 KinBio Recent Development
  • 11.6 Merck
    • 11.6.1 Merck Company Details
    • 11.6.2 Merck Business Overview
    • 11.6.3 Merck Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Introduction
    • 11.6.4 Merck Revenue in Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer Business (2015-2020)
    • 11.6.5 Merck Recent Development

12Analyst's Viewpoints/Conclusions

    13Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Type, the product can be split into
    Pertuzumab
    Trastuzumab

    Market segment by Application, split into
    Combination Therapy
    Mono Therapy

    Based on regional and country-level analysis, the Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia-Pacific
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of Middle East & Africa

    In the competitive analysis section of the report, leading as well as prominent players of the global Mono-Antibody (mAb) for HER2-Positive Advanced Breast Cancer market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    Roche
    BOC Sciences
    LGM Pharma
    Biotechnica Pharma Global
    KinBio
    Merck

    Buy now